AstraZeneca Fights To Revive Diabetes Drug Patent Protection
AstraZeneca on Wednesday sought to reinstate supplementary patent protection for its billion-dollar diabetes drug dapagliflozin, telling a London appeals court that a judge was wrong to rule the patent was invalid....To view the full article, register now.
Already a subscriber? Click here to view full article